India’s GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly lower prices. Analysts predict the market will reach Rs 12,000 crore in five years. This expansion targets millions of diabetics and obese individuals. Companies are competing with innovative pricing and product offerings, promising wider access to these crucial treatments.
Source :- Markets-Economic Times Read More
